The various investor presos we've seen imply that Pro will target severe hearing loss and will be comparable with traditional hearing aids in terms of the hearing loss remediated. I'm expecting Pro to be a significant step change over Max, and the recent trials and other FDA compliance and approval processes indicate Pro will be a fully fledged hearing aid and categorised as such by the FDA. Whether they retail for US$1500 remains to be seen, but I think we're definitely looking at over US$1000 as the entry point for Pro.
- Forums
- ASX - By Stock
- Ann: Nuheara Clinical Trial and FDA 510(K) Pathway Update
The various investor presos we've seen imply that Pro will...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUH (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.91M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NUH (ASX) Chart |
Day chart unavailable